Evidence map›Paper›PMID 33818226›Full record

ArticleAnnals of medicine2021

Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.

Marita Knudsen Pope, Dan Atar, Arne Svilaas, Torstein Hole, Jørn Dalsgaard Nielsen, Ulrik Hintze, Milita Crisby, Pekka Raatikainen, K E Juhani Airaksinen, Saverio Virdone and 8 more

Registry-linked trialAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01090362 (Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01090362 completednot on this map

Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.

TypeobservationalSponsorThrombosis Research InstituteRan2009 to 2020Enrolled57,250ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marita Knudsen PopeInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Dan AtarInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0003-1513-8793
Arne SvilaasNymoen Medical Centre, Kongsberg, Norway.
Torstein HoleClinic of Medicine and Rehabilitation, More and Romsdal Hospital Trust, Alesund, Norway.
Jørn Dalsgaard NielsenDepartment of Cardiology, Copenhagen University Hospital, Copenhagen University, Copenhagen, Denmark.
Ulrik HintzeDepartment of Cardiology, Hospital of South West Jutland, Esbjerg, University of Southern Denmark, Denmark.
Milita CrisbyDepartment of Neurobiology, Care Science and Society, Karolinska University Hospital, Stockholm, Sweden.
Pekka RaatikainenDepartment of Cardiology, Heart and Lung Center, Helsinki University Hospital, Tampere, Finland.
K E Juhani AiraksinenHeart Centre, Turku University Hospital and University of Turku, Turku, Finland.ORCID 0000-0002-0193-568X
Saverio VirdoneThrombosis Research Institute, London, UK.
Karen PieperThrombosis Research Institute, London, UK.
Gloria KayaniThrombosis Research Institute, London, UK.
Jean-Yves Le HeuzeyGeorges Pompidou Hospital, René Descartes University, Paris, France.
Jan SteffelDivision of Electrophysiology and Pacing, Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland.
Janina StepinskaInstitute of Cardiology, Intensive Cardiac Therapy Clinic, Warsaw, Poland.
Jean-Pierre BassandThrombosis Research Institute, London, UK.
A John CammCardiology Clinical Academic Group Molecular & Clinical Sciences Research Institute, St. George's University of London, London, UK.
GARFIELD-AF Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries.

methodsWe examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries.

resultsA total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA

conclusionNordic patients had significantly higher major bleeding than Non-Nordic-European patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE were comparable. CLINICAL

trial registrationUnique identifier: NCT01090362. URL: http://www.clinicaltrials.gov. KEY MESSAGE: Nordic countries had significantly higher major bleeding than Non-Nordic-European countries. Rates of mortality and non-haemorrhagic stroke/SE were similar .

Indexed as

AgedAged, 80 and overAnticoagulantsAtrial FibrillationCause of DeathDrug PrescriptionsDrug Therapy, CombinationEmbolismEuropeFemaleFibrinolytic AgentsHumansMaleMiddle AgedPlatelet Aggregation InhibitorsProspective StudiesAnticoagulantsFibrinolytic AgentsPlatelet Aggregation Inhibitorsantithrombotic treatmentAtrial fibrillationNordic countriesstroke prevention

Identifiers

PMID33818226
PMCPMC8023647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.